Evidence map›Paper›PMID 35316825›Full record

ArticlePloS one2022

Increased yield of AP-3 by inactivation of asm25 in Actinosynnema pretiosum ssp. auranticum ATCC 31565.

Hong Cheng, Guoqing Xiong, Yi Li, Jiaqi Zhu, Xianghua Xiong, Qingyang Wang, Liancheng Zhang, Haolong Dong, Chen Zhu, Gang Liu and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Hong ChengInstitutes of Physical Science and Information Technology, Anhui University, Hefei, China.
Guoqing XiongInstitutes of Physical Science and Information Technology, Anhui University, Hefei, China.
Yi LiAcademy of Military Medical Sciences, Beijing, China.
Jiaqi ZhuAcademy of Military Medical Sciences, Beijing, China.
Xianghua XiongAcademy of Military Medical Sciences, Beijing, China.
Qingyang WangAcademy of Military Medical Sciences, Beijing, China.
Liancheng ZhangAcademy of Military Medical Sciences, Beijing, China.
Haolong DongAcademy of Military Medical Sciences, Beijing, China.
Chen ZhuAcademy of Military Medical Sciences, Beijing, China.
Gang LiuAcademy of Military Medical Sciences, Beijing, China.
Huipeng ChenAcademy of Military Medical Sciences, Beijing, China.ORCID 0000-0002-3405-693X
Academy of Military Medical Sciences · CNAnhui University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asamitocins are maytansinoids produced by Actinosynnema pretiosum ssp. auranticum ATCC 31565 (A. pretiosum ATCC 31565), which have a structure similar to that of maytansine, therefore serving as a precursor of maytansine in the development of antibody-drug conjugates (ADCs). Currently, there are more than 20 known derivatives of ansamitocins, among which ansamitocin P-3 (AP-3) exhibits the highest antitumor activity. Despite its importance, the application of AP-3 is restricted by low yield, likely due to a substrate competition mechanism underlying the synthesis pathways of AP-3 and its byproducts. Given that N-demethylansamitocin P-3, the precursor of AP-3, is regulated by asm25 and asm10 to synthesize AGP-3 and AP-3, respectively, asm25 is predicted to be an inhibitory gene for AP-3 production. In this study, we inactivated asm25 in A. pretiosum ATCC 31565 by CRISPR-Cas9-guided gene editing. asm25 depletion resulted in a more than 2-fold increase in AP-3 yield. Surprisingly, the addition of isobutanol further improved AP-3 yield in the asm25 knockout strain by more than 6 times; in contrast, only a 1.53-fold increase was found in the WT strain under the parallel condition. Thus, we uncovered an unknown function of asm25 in AP-3 yield and identified asm25 as a promising target to enhance the large-scale industrial production of AP-3.

Indexed as

ActinobacteriaMaytansineBiosynthetic PathwaysansamitocinsMaytansine

Identifiers

PMID35316825
PMCPMC8939807
OpenAlexW4220833673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.